| Name | Title | Contact Details |
|---|
Sunovian is a Fort Lee, NJ-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Metavention is a venture-backed medical device company founded in 2012 that is developing a novel glucose control therapy for patients with type 2 diabetes. Metabolic Neuromodulation Therapy (MNT) is a simple cardiovascular procedure intended to modulate sympathetic nervous system activity in patients with Type 2 diabetes for the purpose of lowering blood glucose levels. MNT was developed based on published scientific data and extensive animal studies suggesting a link between elevated sympathetic nerve activity in the metabolic system and increased levels of blood glucose. MNT is currently being studied in human clinical trials and represents a potentially important new treatment option for patients with Type 2 Diabetes.
Verastem Oncology (Nasdaq: VSTM) is a biopharmaceutical company focused on developing and commercializing medicines to improve the survival and quality of life of cancer patients. We are driven by the strength, tenacity and courage of those battling cancer – single-minded in our resolve to deliver new therapies that not only keep cancer at bay but improve the lives of patients diagnosed with cancer. Because for us, it`s personal. Our team is anchored by core values of character, urgency, respect and excellence. We pride ourselves in being an organization committed to diversity and inclusion in order to achieve and sustain excellence. We believe that empowering employees is what makes them truly care about the important work they do.
Octave is developing a comprehensive, first-in-class Care Management Platform.
IO Biotech is a clinical stage biotech company developing disruptive immune therapies for immunological treatment of cancer. Our pipeline of first-in-class immune modulating anti-cancer therapies is based on a unique platform technology enabling the activation of T cells that are specific for immune inhibitory molecules. IO Biotech has achieved a proven track record of progressing compounds to the clinic, and has two lead immune modulating anti-cancer therapies targeting IDO and PD-L1 in clinical development and several compounds finalizing preclinical phase. IO Biotech has an experienced management team within immuno-oncology fields and a world-class advisory board.